Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would love to see a huge contract $$$
I would love to see a huge contract $$$
NEWS ARE VERY CLOSE.DID YOU GUYS GET TO SEE THE 7 MILLION BID SUPPORT AT .0075S?WOW.WE WILL SEE HOW HIGH IT WILL RUN NO THE NEWS SOON.FORWARD LOOKING EVENT IS DUE ANY DAY NOW.
Over one million on the bid
0.01's this week before news would be nice. Hopefully, 0.02 - 0.05+ after this news.
Hopefully we get over two and hold.
I SEE .02 TO AS HIGH AS .10 THIS YEAR IMO.PER WHAT I READ IN THE LAST PR FROM CEO.HUGE CONTRACTS.COMING IMO.WE SHOULD MOVING UP TO .01 ARE THIS WEEK IMO.
4TH WEEK IS THIS WEEK.READ ALL BOLD MARKS:))THE NEWS WAS JUNE 22ND
MONDAY IS JULY 18TH:))LARGE SCALE DISTRIBUTIONS AFTER THE NEWS ON TESTING.DAMN.WALMARTS???CVs???WALGREENS???PUBLIX??ALDI???THE LIST WILL NOT END.ONCE IT STARTS BAMMMMMMMMMMMMM
The Company expects the additional testing will be completed within four weeks and product distribution is expected to commence soon after.
ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products
Press Release | 06/22/2022
LOS ANGELES, June 22, 2022 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM) announces plans to conduct additional internal quality control testing for their new Vitastem products. Vitastem and Vitastem Ultra are manufactured at a contract facility in the United States and have successfully undergone all standard testing required by regulators. Following extensive consultation with the Company’s manufacturing partners and potential purchasers and distributors of the products, the decision was made to implement further testing as an additional precautionary measure since both products are using new formulations.
The new and improved Vitastem and Vitastem Ultra are FDA-registered drugs and are among the strongest and most effective topical antibiotics available on the market. Vitastem kills all harmful Gram-positive and Gram-negative bacteria that have been available for testing (bacteria that is associated with acne, cuts, scrapes, burns, and secondary infections associated with psoriasis and eczema). Vitastem Ultra uses bacitracin as the active ingredient and the new formula is clear and colorless compared to the brownish color of the original (which has tetracycline as the active ingredient), so it will not stain the skin, fingernails, toenails, or anywhere else it is applied. Both Vitastem and Vitastem Ultra work similarly and provide the same great results. The new formulation with bacitracin provides an alternative for consumers who are allergic or resistant to one or the other.
President and CEO, Dr. Chris Otiko said, “Since both of these products are a new and improved formulation, we decided now would be the best time to conduct additional testing before we begin large scale distribution.”
Dr. Otiko continued, “The products have tested well so far, and we expect they will continue to do so without issue, but because they are both different formulations than the original, and since we are moving much closer to having to fulfill large purchase orders, we felt we should implement these precautionary measures at this time in an abundance of caution. The last thing we want is to have a problem down the road when a correction would be much harder to address. Taking this step now will minimize the potential for such problems later.”
The Company expects the additional testing will be completed within four weeks and product distribution is expected to commence soon after.
Wrong!!! You can’t and shouldn’t judge anyone by looking at their past. It has been proven, by experts and millionaires that’s not how you start (The Past) that matters, is how you end (The Future) that counts!!! I ain’t setting myself for a disappointment, I am a business man and investor, if you have experienced such feelings on this before and can’t bare to see such to happen, then you shouldn’t be here. This is not for you mate!!! I have done this for a long time and I know how perfectly the OTC works… Get some popcorn and a Coca!!! Relax mate, chill and enjoy the ride
Would be nice,GL.
IMHO, we should have news during coming week.
You can only judge a person's future response/actions by their past response/actions.
"Are we going to hit the 3rd or 4th week to finalize the tests?"
Please do not set your self up for a disappointment.
Allow much more time,
IMHO(In My Humble Opinion)
Are we going to hit the 3rd or 4th week to finalize the tests? Can’t wait for CEO updates on these tests…. This is going to be epic
The past don't matter It's all about where we are
BUT BUT BUT
There have been MANY previous "BIG NAMES" in past PR's. Problem is, teh PR's, like ALL, are VAGUE and do not name them but sure do say words like "BIG" "Major" etc.
LMFAO!!!
If a PR about the likes of a company like CVS, Walgreens or Walmart signs a deal, that’s think there is a fair chance to see even a touch of green paper in my honest opinion.
AHAHAHAHAHA!!!! Right. Cause if that were to happen then peeps can actually verify things :)
If that happens we see $Don't laugh it happens
If a PR about the likes of a company like CVS, Walgreens or Walmart signs a deal, that’s think there is a fair chance to see even a touch of green paper in my honest opinion.
Just one new big name account we see silver
I SMELL NEWS NEXT WEEK ON THE 4 WEEK TEST.:))
READ ALL BOLD MARKS:))THE NEWS WAS JUNE 22ND
MONDAY IS JULY 18TH:))LARGE SCALE DISTRIBUTIONS AFTER THE NEWS ON TESTING.DAMN.WALMARTS???CVs???WALGREENS???PUBLIX??ALDI???THE LIST WILL NOT END.ONCE IT STARTS BAMMMMMMMMMMMMM
The Company expects the additional testing will be completed within four weeks and product distribution is expected to commence soon after.
ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products
Press Release | 06/22/2022
LOS ANGELES, June 22, 2022 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM) announces plans to conduct additional internal quality control testing for their new Vitastem products. Vitastem and Vitastem Ultra are manufactured at a contract facility in the United States and have successfully undergone all standard testing required by regulators. Following extensive consultation with the Company’s manufacturing partners and potential purchasers and distributors of the products, the decision was made to implement further testing as an additional precautionary measure since both products are using new formulations.
The new and improved Vitastem and Vitastem Ultra are FDA-registered drugs and are among the strongest and most effective topical antibiotics available on the market. Vitastem kills all harmful Gram-positive and Gram-negative bacteria that have been available for testing (bacteria that is associated with acne, cuts, scrapes, burns, and secondary infections associated with psoriasis and eczema). Vitastem Ultra uses bacitracin as the active ingredient and the new formula is clear and colorless compared to the brownish color of the original (which has tetracycline as the active ingredient), so it will not stain the skin, fingernails, toenails, or anywhere else it is applied. Both Vitastem and Vitastem Ultra work similarly and provide the same great results. The new formulation with bacitracin provides an alternative for consumers who are allergic or resistant to one or the other.
President and CEO, Dr. Chris Otiko said, “Since both of these products are a new and improved formulation, we decided now would be the best time to conduct additional testing before we begin large scale distribution.”
Dr. Otiko continued, “The products have tested well so far, and we expect they will continue to do so without issue, but because they are both different formulations than the original, and since we are moving much closer to having to fulfill large purchase orders, we felt we should implement these precautionary measures at this time in an abundance of caution. The last thing we want is to have a problem down the road when a correction would be much harder to address. Taking this step now will minimize the potential for such problems later.”
The Company expects the additional testing will be completed within four weeks and product distribution is expected to commence soon after.
I’m getting jealous, have to nibble some on my lunch break!! Go $VDRM$!!
I TOOK THE REST OF THE .008S.EVERYONE IS BROKE SO SOMEONE HAS TO DO IT.LOL.
PICKING UP .0078,0079,AND .008.
07/15/2022 10:08:11 Bought 100000 VDRM @ 0.0078
-783.00 3.00 0.00
07/15/2022 10:08:35 Bought 15931 VDRM @ 0.0078
-127.26 3.00 0.00
07/15/2022 10:08:48 Bought 10000 VDRM @ 0.0079
-79.00 0.00 0.00
07/15/2022 10:08:48 Bought 4700 VDRM @ 0.0079
-37.13 0.00 0.00
07/15/2022 10:08:59 Bought 13500 VDRM @ 0.008
-108.00 0.00 0.00
07/15/2022 10:09:04 Bought 155869 VDRM @ 0.008
-1,246.95
Too late to edit last post...brain overload...Go $VDRM. Go $ALKM while we're at it.
Picked up another 259,000 shares today @ .0077. Go $ALKM
IT WILL GO BALLISTIC IMO.
When it happens, it will be fast… VDRM is the next ENZOLYTICS but without God Father’s Pumping. Millionaire on the making. Zip code changer
Okay thanks for the feedback
Fasten seat belt hang on to your A$$
WHEN NEWS HITS,MAKE SURE YOU WATCH LEVEL II.LOL
WE WILL SEE HOW HIGH IT WILL GO.EXPECT TO SEE 5 TO 10 MILLION ON THE BIDS.AT THAT TIME CHASHING.
No Interest. More VAGUE PR's dangling the Carrot with complete Vagueness....
As usual.
I just tested it with a small 10K order, it went through at .0077
Is VDRM halted? No orders!!! Something is cooking on the backend kitchen
Is VDRM halted? No orders!!! Something is cooking on the backend kitchen
FORWARD LOOKING EVENT ANYDAY.The Company expects the additional testing will be completed within four weeks and product distribution is expected to commence soon after.
READING THE LAST PR ANYDAY NOW.READING BOLD AREA IN THIS NEWS,IT LOOKS INCREDIBLE.WE WILL SEE WHAT HAPPENS.HOPING FOR .02 TO AS HIGH AS .07 IF THE NEWS IS VERY POSITIVE,AND HUGE CONTRACTS TAKE PLACE.READ BOLD PARTS
The Company expects the additional testing will be completed within four weeks and product distribution is expected to commence soon after.
ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products
Press Release | 06/22/2022
LOS ANGELES, June 22, 2022 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM) announces plans to conduct additional internal quality control testing for their new Vitastem products. Vitastem and Vitastem Ultra are manufactured at a contract facility in the United States and have successfully undergone all standard testing required by regulators. Following extensive consultation with the Company’s manufacturing partners and potential purchasers and distributors of the products, the decision was made to implement further testing as an additional precautionary measure since both products are using new formulations.
The new and improved Vitastem and Vitastem Ultra are FDA-registered drugs and are among the strongest and most effective topical antibiotics available on the market. Vitastem kills all harmful Gram-positive and Gram-negative bacteria that have been available for testing (bacteria that is associated with acne, cuts, scrapes, burns, and secondary infections associated with psoriasis and eczema). Vitastem Ultra uses bacitracin as the active ingredient and the new formula is clear and colorless compared to the brownish color of the original (which has tetracycline as the active ingredient), so it will not stain the skin, fingernails, toenails, or anywhere else it is applied. Both Vitastem and Vitastem Ultra work similarly and provide the same great results. The new formulation with bacitracin provides an alternative for consumers who are allergic or resistant to one or the other.
President and CEO, Dr. Chris Otiko said, “Since both of these products are a new and improved formulation, we decided now would be the best time to conduct additional testing before we begin large scale distribution.”
Dr. Otiko continued, “The products have tested well so far, and we expect they will continue to do so without issue, but because they are both different formulations than the original, and since we are moving much closer to having to fulfill large purchase orders, we felt we should implement these precautionary measures at this time in an abundance of caution. The last thing we want is to have a problem down the road when a correction would be much harder to address. Taking this step now will minimize the potential for such problems later.”
The Company expects the additional testing will be completed within four weeks and product distribution is expected to commence soon after.
Did we jinx it?? Lol
Only a matter of time. I am expecting good news from the test/study, and hoping for update on large distributions. That news could be coming any day now. Beyond that, this company has plenty of room to scale while being more efficient. All the while collecting residual income
Too many Pennie’s out there buried in debt with hope. This one here… Is REAL
Has been trading well the past 5 days. Big munch on that wall @ that .0076 offer, showing strength . I think things are falling into place and it’s all about this clear product!
Agree 100%, Glad to see the buying interest.
Haven’t had a 3MM volume day in a month. Techs looking bullish. It won’t be held down forever!
Doesn’t take much to move this thing! Could be the last week to load at reasonable prices.
Come on, $VDRM! 0.05-0.10+ run starting next week!
Looking forward to a x 10!
Closed at 8,, soon no longer terrible sub Penny
Are you that hungry? Give the Dr. a chance
Followers
|
615
|
Posters
|
|
Posts (Today)
|
15
|
Posts (Total)
|
73875
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |